PMH35 TREATMENT INITIATION WITH ATOMOXETINE VS. STIMULANTS FOR ADULTS WITH ADHD IN MEDICAID SETTINGS  by Ye, W et al.
A81Abstracts
Hispanic Caucasian (NHC) patients in a managed care plan.
METHODS: A retrospective claims database analysis was con-
ducted using eligibility, pharmacy, and medical claims data from
a large US health plan, supplemented by a linked database 
of socioeconomic characteristics (race, ethnicity, household
income). Patients 6–64 years newly treated with ADHD therapy
between January 1, 2000 and December 31, 2004, with contin-
uous enrollment for 6 months prior and 12 months following
the earliest ADHD prescription were selected. RESULTS: HIS
subjects (N = 2827) were younger (mean age 19.0 vs 21.6 years),
had shorter duration of continuous insurance coverage, and were
in lower income brackets compared to NHC subjects (N =
59,820) (p < 0.001). Anxiety and depression were more com-
monly diagnosed among NHC (16% and 24%) compared to HIS
subjects (13% and 20%). Though rates of single prescription
ﬁlling for ADHD medications were high in both groups (27%),
HIS subjects were less compliant with therapy compared to NHC
subjects. HIS status was a signiﬁcant predictor of total and
ADHD-related health care costs during the follow-up period,
controlling for patient age, index drug, insurance type, and geo-
graphic region. Among HIS, adjusted mean total costs were 21%
lower than among NHC ($3295 vs $4187, p < 0.001); ADHD-
related costs were 29% lower ($696 vs. $986, p < 0.001) for HIS
vs. NHC. HIS subjects had fewer physician ofﬁce and acute care
visits during follow-up. Within race/ethnic groups, increasing
income was associated with increased all cause, but decreased
ADHD-related cost and utilization. CONCLUSION: This study
indicates that total and ADHD-related health care costs are
lower among HIS patients with ADHD than in NHC patients,
with a greater difference for ADHD related costs than total costs.
HIS subjects were less persistent with ADHD therapy and used
fewer health care services compared to NHC subjects.
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OBJECTIVES: To proﬁle antipsychotic use among bipolar dis-
order patients, including antipsychotic type, duration of use,
gaps in therapy, and concurrent mood-stabilizer and antidepres-
sant therapy. METHODS: Bipolar disorder patients with at least
two antipsychotic prescriptions ﬁlled between January 1, 1999,
and December 31, 2001 were extracted from a Medicaid data-
base. Initiation of antipsychotic therapy was indicated by the
absence of claims for antipsychotic medication within 90 days
prior to the ﬁrst prescription. Duration of therapy was calculated
from the ﬁrst prescription ﬁll date to the end of 12 months
follow-up or discontinuation of antipsychotic therapy. Gaps
between reﬁlls were deﬁned as the number of days between the
depletion date and the ﬁll date. A treatment gap category was
calculated for each patient based on the longest continuous gap
between reﬁlls. Antipsychotic use was considered to be ﬁrst-line
treatment if there were no claims for mood-stabilizers in the 12
months before antipsychotic initiation. Prescription claims in the
12-month follow-up period were examined to classify treatments
as antipsychotic alone or combined with mood-stabilizer or anti-
depressant. RESULTS: Among 832 patients initiated on antipsy-
chotics, 75.4% were initiated on atypicals and 24.6% on
typicals. The average duration of therapy was 224.5 (±140.5)
days. In total, 58.9% of patients had gaps between reﬁlls exceed-
ing 30 days, and 22.7% had at least one gap exceeding 90 days.
The average duration of the longest gap was 61.2 (±70.3) days.
Antipsychotics were the ﬁrst-line treatment in 66.8% of patients.
During follow-up, 56.3% of patients used antipsychotics alone,
43.8% used combinations of antipsychotics and mood-stabiliz-
ers, and 73.7% used antipsychotics with antidepressants. CON-
CLUSION: Short duration of antipsychotic use and long gaps in
therapy indicate poor adherence to therapy in bipolar disorder
patients. About two-thirds of patients initiate antipsychotics
before mood-stabilizers. Concomitant use of a mood-stabilizer
or antidepressant with antipsychotic is highly prevalent.
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OBJECTIVES: To examine pharmacologic treatment patterns
for individuals diagnosed with Generalized Anxiety Disorder
(GAD) with comorbid depression and/or pain. METHODS:
Data were from PharMetrics Integrated Outcomes Database.
Patients aged 18–64 were selected if they had a diagnosis of GAD
(ICD9-CM: 30002) between January 2003 and June 2004, pre-
ceded by 6 months without GAD diagnosis, and continuous
enrollment during 6-month prior and 12-month after GAD diag-
nosis. Treatment regimens during the year after GAD diagnosis
were examined for six-classes of psychotropics (anxiolytics, 
antidepressants, anticonvulsants, noradrenergic agents, atypical
antipsychotics, and hypnotics). Comparisons were made for
patients with GAD only versus those with comorbid depression
and/or pain conditions. Poisson regressions controlling patient
demographic and clinical characteristics (including provider spe-
cialty and other comorbidities), were used to evaluate the impact
of depression and pain on GAD treatment patterns. RESULTS:
Of 36,435 patients (mean age 41.5 years, 67% female) included
in this analysis, 23.8% had GAD only, 15.5% GAD/depression,
32.8% GAD/pain, and 28.0% GAD/depression/pain. For
patients with GAD/depression/pain, 48.5% received anxiolytics,
15.7% anticonvulsants, and 15.4% hypnotics, 44.2% received
≥3 and 11.9% ≥6 of different drugs of psychotropics, which 
were all signiﬁcantly higher than other groups. Compared to
GAD/depression patients, GAD/pain received signiﬁcantly more
analgesics (46.2% vs. 21.3%, p < 0.001) and muscle relaxants
(14.5% vs. 3.2%, p < 0.001), and less antidepressants (44.6%
vs. 71.5%, p < 0.001). Regression results from Poisson model
revealed that patients with GAD/depression/pain received 0.67
more classes of and 1.28 more number of psychotropic drugs (p
< 0.001 for both) when compared to GAD only. Similar results
were also observed for patients with GAD/depression and for
those with GAD/pain though to a lesser extent. CONCLUSION:
The ﬁndings suggest that there is a high comorbid prevalence of
depression and pain with GAD. Associated with this high comor-
bidity, complex patterns of polypharmacy are common in the
treatment of GAD.
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OBJECTIVES: To determine factors associated with initiation of
atomoxetine (ATX), stimulants (STIM), or long-acting stimu-
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lants (LA-STIM) in adults with ADHD using Medicaid.
METHODS: Data were from the IMS Health LRx Database.
Patients covered by Medicaid age ≥ 18 years were selected if they
initiated treatment with an ADHD medication categorized as
ATX, any STIM, or LA-STIM between January 2005 and
December 2005. Initiation was deﬁned as ﬁrst use of a medica-
tion preceded by 120 days without a prescription in the same
category. Contrasts of most-recent initiations of ATX vs. LA-
STIM or ATX vs. LA-STIM, were modeled via stepwise logistic
regression. Factors considered were age, gender, prior ADHD
medications, initiation type (treatment naïve, switch, add-on,
reintroduction), concomitant medications, provider specialty,
and line of therapy. RESULTS: A total of 8672 patients (58.04%
female) most recently initiated treatment with ATX, 27,574
(59.72% female) with STIM, and 15,958 (57.02% female) with
LA-STIM. Patients who were more likely to initiate ATX than
STIM (lower conﬁdence bound of adjusted odds ratios > 1) were
males, naïve to therapy, or had taken different ADHD medica-
tions in history prior to the current initiation, had prescriptions
from primary care physicians or nurse practitioners, had pre-
vious use of ATX, or had concomitant use of antidepressants,
antimanics, antipsychotics, anticonvulsants, or sleep aids. 
Conversely, STIM initiation was more likely for patients switch-
ing or being reintroduced to therapy, patients with prior use of
stimulant, having concomitant use with anxiolytics, or receiving
their prescription from neurologists. The model factors selected
for initiation of ATX vs. LA-STIM were consistent with those
for the comparison with STIM. CONCLUSION: The factors sig-
niﬁcantly associated with initiation of ATX vs. STIM or LA-
STIM suggest that therapy with ATX and STIM are addressing
different patient treatment needs. The ﬁndings suggest that 
ATX is preferentially prescribed for patients with psychiatric
comorbidities.
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OBJECTIVES: To model disease progression across multiple
domains in Alzheimer’s disease (AD) patients treated with a
cholinesterase inhibitor in clinical practice. METHODS: 435 AD
patients starting treatment with donepezil in 11 centers in
Sweden were followed up to 3 years. In 6-month intervals data
was collected on cognitive function (ADAS-Cog) physical func-
tion (IADL and PSMS scales), care setting and resource utiliza-
tion. Regression modelling was used to identify determinants of
disease progression rates and to establish equations predicting
progression across multiple domains. A dynamic panel approach
was used to model the 6 months change in cognitive function.
For physical function a random-effects model was ﬁtted using
ADAS-cog and lagged ADAS-cog as explanatory variables. In
both models other patient characteristics (e.g. sex, age, disease
duration and ApoE-genotype) were included when signiﬁcant.
RESULTS: The progression in ADAS-cog was estimated to
increase with higher progression in the previous 6 months
period, i.e. a one point higher progression in the previous period
would translate into 0.4 points higher progression in the present
cycle. Also, patients having at least one ApoE ε2 but no ApoE
ε4 allele were estimated to have about 2 points higher progres-
sion. Both IADL and PSMS scores were estimated to decrease
with higher present and lagged ADAS-cog scores (between 0.03
and 0.06 points for each ADAS-cog point) and higher disease
duration (0.14 to 0.2 points for each year). Also, male patients
were estimated to have 0.46 points lower IADL scores. CON-
CLUSION: The estimated regression functions can be used in a
regression model for simulation of long term disease progression.
Adding treatment effects and resource utilization linked to
disease severity this enables a dynamic framework for economic
evaluation of any treatment intervention.
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OBJECTIVES: Evaluate persistence and compliance patterns
with once-daily galantamine ER vs. twice-daily galantamine IR
and with galantamine ER vs. twice-daily rivastigmine in an
employer-based retiree health beneﬁt claims database.
METHODS: Data were obtained from a 9 million member
health beneﬁt claims database. Patients > 60 years with at least
one claim for galantamine ER, IR, or rivastigmine during the
period 1/1/05–2/28/06 were eligible, with the ﬁrst prescription
as the index event. Patients had 6 months continuous enrollment
pre- and post-index date. Galantamine ER patients were
matched up to 1 : 3 to IR and rivastigmine patients based on
propensity for galantamine ER therapy. Demographic and clini-
cal characteristics were evaluated pre- and post- propensity
matching using descriptive statistics for matched-pairs designs
(e.g., t-tests, ÷2 tests). Persistence was evaluated across matched-
pair sets by measuring duration of continuous therapy from
index date to a gap of more than twice the days supplied for the
previous reﬁll. Compliance with each treatment was assessed
using medication possession ratio (MPR), calculated as total
days supplied divided by total follow-up duration (180 days).
Wilcoxon signed rank tests were performed to compare persis-
tence and compliance measures for each matched-pair set.
RESULTS: The study included 743 galantamine ER versus 1611
IR and 812 galantamine ER versus 1712 rivastigmine users.
Demographic characteristics were similar between study groups.
Mean age was 78.9 years, 55% were women, and 99% were
institutionalized. Mean 6-month follow-up persistency rates
were longer for galantamine ER versus IR (136.2 vs 128.7 days;
p = 0.001) and for galantamine ER vs rivastigmine (135.1 vs
130.1 days; p = 0.029). Mean 6-month follow-up MPR was
higher for galantamine ER vs IR (0.60 vs 0.55; p < 0.01) and
trended higher for galantamine ER vs rivastigmine (0.60 vs 0.58;
p = 0.083). CONCLUSION: Our ﬁndings suggest once-daily
galantamine ER is associated with greater persistence and com-
pliance versus galantamine IR or rivastigmine.
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OBJECTIVES: Among the challenges in assessing persistence
with medication time to all-cause discontinuation with pharmacy
claims data are the potential variations in persistence deﬁnitions
and data-cutting criteria. This study compared persistence on
